公开(公告)号：US12157733B2

公开(公告)日：2024-12-03

申请号：US17116016

申请日：2020-12-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US11618753B2

公开(公告)日：2023-04-04

申请号：US16963886

申请日：2019-01-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Carolyn Diane Dzierba ,  Hua Gong ,  Jason M. Guernon ,  Junqing Guo ,  Amy C. Hart ,  Guanglin Luo ,  John E. Macor ,  William J. Pitts ,  Jianliang Shi ,  Brian Lee Venables ,  Carolyn A. Weigelt ,  Yong-Jin Wu ,  Zhizhen Barbara Zheng ,  Sing-Yuen Sit ,  Jie Chen

IPC: A61K31/53 ,  C07D253/08 ,  C07D487/04

Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

公开(公告)号：US20220315580A1

公开(公告)日：2022-10-06

申请号：US17116016

申请日：2020-12-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US20200347071A1

公开(公告)日：2020-11-05

申请号：US16963886

申请日：2019-01-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Carolyn Diane Dzierba ,  Hua Gong ,  Jason M. Guernon ,  Junqing Guo ,  Amy C. Hart ,  Guanglin Luo ,  John E. Macor ,  William J. Pitts ,  Jianliang Shi ,  Brian Lee Venables ,  Carolyn A. Weigelt ,  Yong-Jin Wu ,  Zhizhen Barbara Zheng ,  Sing-Yuen Sit ,  Jie Chen

IPC: C07D487/04

Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

公开(公告)号：US20250074909A1

公开(公告)日：2025-03-06

申请号：US18928275

申请日：2024-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

公开(公告)号：US10913738B2

公开(公告)日：2021-02-09

申请号：US16484604

申请日：2018-02-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06 ,  A61P1/00

Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

公开(公告)号：US20220213099A1

公开(公告)日：2022-07-07

申请号：US17609021

申请日：2020-05-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. DYCKMAN ,  Murugaiah Andappan Murugaiah Subbaiah

IPC: C07D471/04 ,  C07F9/09

Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV): or salts thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using the compounds as prodrugs of an inhibitor of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These prodrugs compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20190389859A1

公开(公告)日：2019-12-26

申请号：US16484604

申请日：2018-02-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Amy C. Hart ,  John E. Macor ,  Michael E. Mertzman ,  William J. Pitts ,  Steven H. Spergel ,  Scott Hunter Watterson ,  Murugaiah Andappan Murugaiah Subbaiah ,  Jie Chen ,  Carolyn Diane Dzierba ,  Guanglin Luo ,  Jianliang Shi ,  Sing-Yuen Sit

IPC: C07D471/04

Abstract: Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).

公开(公告)号：US20230167082A1

公开(公告)日：2023-06-01

申请号：US17627169

申请日：2020-07-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ryan M. Moslin ,  David S. Weinstein ,  Thangeswaran Ramar ,  Murugaiah Andappan Murugaiah Subbaiah

IPC: C07D401/12 ,  C07D403/12

CPC classification number: C07D401/12 ,  C07D403/12

Abstract: There are disclosed prodrugs of the compounds of the formula. The prodrugs are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US11447449B2

公开(公告)日：2022-09-20

申请号：US16959487

申请日：2019-01-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Steven P. Seitz ,  David K. Williams ,  Murugaiah Andappan Murugaiah Subbaiah

IPC: C07C275/42 ,  C07K16/28

Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.